CRVS - Corvus Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Burlingame,
United States
Type: Equity
CRVS price evolution
CRVS
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $14.84 | $7.46 | $12.62 | $20.11 |
| Short term investments | $32.41 | $14.67 | $14.53 | $12.06 |
| Net receivables | $0.04 | $0.03 | $0.03 | $0.01 |
| Inventory | ||||
| Total current assets | $48.26 | $22.85 | $27.96 | $33.09 |
| Long term investments | $15.4 | $16.07 | $16.12 | $17.07 |
| Property, plant & equipment | $0.77 | $1.08 | $1.39 | $1.69 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $16.3 | $17.23 | $17.6 | $18.85 |
| Total investments | $47.81 | $30.74 | $30.65 | $29.14 |
| Total assets | $64.56 | $40.08 | $45.55 | $51.94 |
| Current liabilities | ||||
| Accounts payable | $1.21 | $1.61 | $1.52 | $1.4 |
| Deferred revenue | ||||
| Short long term debt | $0.7 | $1.04 | $1.37 | $1.34 |
| Total current liabilities | $13.34 | $6.72 | $6.87 | $7.3 |
| Long term debt | $0.35 | |||
| Total noncurrent liabilities | $0.35 | |||
| Total debt | $0.7 | $1.04 | $1.37 | $1.69 |
| Total liabilities | $13.34 | $6.72 | $6.87 | $7.65 |
| Shareholders' equity | ||||
| Retained earnings | -$344.68 | -$340.42 | -$334.72 | -$328.06 |
| Other shareholder equity | -$1.35 | -$1.27 | -$0.97 | -$1.44 |
| Total shareholder equity | $51.23 | $33.36 | $38.68 | $44.29 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $12.62 | $13.16 | $63.46 | $16.45 |
| Short term investments | $14.53 | $29.14 | $5.99 | $27.8 |
| Net receivables | $0.03 | $0.59 | $0.51 | |
| Inventory | ||||
| Total current assets | $27.96 | $43.66 | $71.31 | $45.34 |
| Long term investments | $16.12 | $21.88 | $34.27 | $37.23 |
| Property, plant & equipment | $1.39 | $2.57 | $3.64 | $2.55 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $17.6 | $24.58 | $38.14 | $40.19 |
| Total investments | $30.65 | $51.02 | $40.26 | $65.03 |
| Total assets | $45.55 | $68.24 | $109.45 | $85.53 |
| Current liabilities | ||||
| Accounts payable | $1.52 | $1.98 | $1.56 | $3.47 |
| Deferred revenue | ||||
| Short long term debt | $1.37 | $1.23 | $1.05 | $1.08 |
| Total current liabilities | $6.87 | $10.75 | $9.69 | $12.15 |
| Long term debt | $1.37 | $2.6 | $1.23 | |
| Total noncurrent liabilities | $1.37 | $2.6 | $1.23 | |
| Total debt | $1.37 | $2.6 | $3.65 | $2.31 |
| Total liabilities | $6.87 | $12.13 | $12.29 | $13.38 |
| Shareholders' equity | ||||
| Retained earnings | -$334.72 | -$307.69 | -$266.38 | -$223.14 |
| Other shareholder equity | -$0.97 | -$0.56 | $1.87 | $0 |
| Total shareholder equity | $38.68 | $56.12 | $97.16 | $72.15 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $4.11 | $4.08 | $4 | $3.96 |
| Selling, general & administrative | $1.82 | $2.18 | $1.65 | $1.59 |
| Total operating expenses | $5.93 | $6.25 | $5.65 | $5.56 |
| Operating income | -$5.93 | -$6.25 | -$5.65 | -$5.56 |
| Income from continuing operations | ||||
| EBIT | -$4.26 | -$5.7 | -$6.65 | -$6 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$4.26 | -$5.7 | -$6.65 | -$6 |
| Income (for common shares) | -$4.26 | -$5.7 | -$6.65 | -$6 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $16.53 | $24.47 | $29.11 | $31.83 |
| Selling, general & administrative | $6.88 | $8.1 | $9.52 | $11.93 |
| Total operating expenses | $23.41 | $32.54 | $38.63 | $43.76 |
| Operating income | -$23.41 | -$32.54 | -$38.63 | -$43.76 |
| Income from continuing operations | ||||
| EBIT | -$27.03 | -$41.31 | -$43.24 | -$6 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$27.03 | -$41.31 | -$43.24 | -$6 |
| Income (for common shares) | -$27.03 | -$41.31 | -$43.24 | -$6 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$4.26 | -$5.7 | -$6.65 | -$6 |
| Operating activities | ||||
| Depreciation | $0.02 | $0.02 | $0.03 | $0.03 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.77 | $0.69 | $0.57 | $0.55 |
| Total cash flows from operations | -$5.48 | -$5.16 | -$5.17 | -$5.43 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | -$17.5 | -$0.01 | -$2.32 | $17.55 |
| Total cash flows from investing | -$17.5 | -$0.01 | -$2.32 | $17.55 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $30.37 | $0.34 | ||
| Net borrowings | ||||
| Total cash flows from financing | $30.37 | $0.34 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $7.38 | -$5.16 | -$7.49 | $12.45 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$27.03 | -$41.31 | -$43.24 | -$6 |
| Operating activities | ||||
| Depreciation | $0.15 | $0.37 | $0.46 | $0.63 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.15 | $2.69 | $4.23 | $5.75 |
| Total cash flows from operations | -$23.93 | -$27.02 | -$36.72 | -$34.78 |
| Investing activities | ||||
| Capital expenditures | -$0.03 | -$0.25 | -$0.01 | -$0.08 |
| Investments | $15.57 | -$23.03 | $21.57 | $44.84 |
| Total cash flows from investing | $15.54 | -$23.28 | $21.56 | $44.77 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $7.86 | $62.16 | $1.31 | |
| Net borrowings | ||||
| Total cash flows from financing | $7.86 | $62.16 | $1.31 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$0.54 | -$50.3 | $47 | $11.3 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$22.51M |
| EBIT | -$22.62M |
| Net Income | -$22.62M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -44.75% |
| ROE | -53.99% |
| Debt/Equity | 0.18 |
|---|---|
| Net debt/EBITDA | 0.07 |
| Current ratio | 3.62 |
| Quick ratio | 3.62 |